BRAIN+ DEVELOPS
DIGITAL MEDICINE
FOR ALZHEIMER’S
AND DEMENTIA

Brain+ develops Digital Therapeutics for Alzheimer’s and dementia, presenting a unique opportunity to invest in a growing megatrend at the frontier of health care digitalisation

BRAIN+’ NEW PRODUCT FOR DEMENTIA LAUNCHING Q4 2022

BRAIN+ DEVELOPS DIGITAL MEDICINE FOR ALZHEIMER’S AND DEMENTIA

Brain+ develops Digital Therapeutics for Alzheimer’s and dementia, presenting a unique opportunity to invest in a growing megatrend at the frontier of health care digitalisation

BRAIN+’ NEW PRODUCT FOR DEMENTIA LAUNCHING Q4 2022

MEET BRAIN+

WHY INVEST IN BRAIN+

The mission of Brain+ is to restore patients’ independence and quality of life by treating and detecting cognitive decline in Alzheimer’s disease and dementia through digital means. Brain+ has developed a set of Digital Medicine technologies, which enable the company to create a unique and differentiated product offering. These technologies, combined with a strong clinical pipeline, Brain+ is in a strong position to grow towards a market leader position in the major Digital Medicine space.
Kim
Have questions?

Fill out this form
and get contacted by:

Kim Baden-Kristensen
CEO & Co-founder

INVESTOR EVENTS

2022

26 August

Dansk Aktionærforening

Interview with Kim Baden-Kristensen, CEO about dementia product launch in Q4

29 August

Økonomisk Ugebrev

Life Science Investor Conference

31 August

Finwire

Hemma Hos

12 September

Aktiespararna

Aktiedagen Stockholm

14 September

BioStock

Investor Showcase Stockholm

4 October

Fill or Kill

Podcast

4 October

Dansk Aktionærforening

Interview

14 October

ProInvestor

Interview

19 September

Finwire

Sitdown interview

2021

20 December 16:00

DANSK AKTIONÆRFORENING EVENT

Q&A session with Dansk Aktionærforening, talking about the IPO and news of first large-pharma partnership deal.

23 September 16:00

DANSK AKTIONÆRFORENING EVENT

Mikael Bak hosts Brain+ for a company presentation and subsequent session for investors to ask questions.

22 September 16:00

Nordnet Q&A

A chance for investors to ask questions live to Brain+

17 September

Nordnet interview:

A glimpse into Brain+, speaking on the strategy and goals.

16 September

Finwire interview:

Hear from Kim Baden-Kristensen, CEO & Co-Founder, on Brain+ and the plans after the IPO

16 September

ProInvestor interview:

Helge Larsen goes in-depth with Brain+, to discuss Digital Medicine, and how Brain+ will make a difference.

OlderMan-Phone-shutterstock_1877563882-1920x1080

DIGITAL MEDICINE – A GLOBAL HEALTH TREND

The digital medicine trend is the next big thing at the frontier of digitalisation and has already proven a powerful way of dealing with several important diseases, where traditional, chemical medicines have failed. Software-based treatments/therapies have become FDA-approved and several large pharma companies have joined the game. With a current compounded annual growth rate of 23,1% the market size for digital medicine is projected to hit 19,1 billion USD by 2028.

Holding hands

TREATING DEMENTIA AND ALZHEIMER’S
WITH DIGITAL MEDICINE

Dementia and Alzheimer’s are both conditions, where digital medicine has proven to have a significant impact. And with dementia on the rise globally with 50 million people currently diagnosed (a number which is expected to more than triple to 152 million people by 2050), this presents a global addressable market for digital dementia treatments of approximately 2 to 5 billion USD in 10 to 15 years from today.

Holding hands
Digital Therapeutics on Smart Device

FURTHER ANCHORING BRAIN+ AS
A MARKET LEADER

The IPO will fund further product development and advancing towards the phase 3 clinical trials needed for regulatory approval in order to attract major pharma companies for strategic partnerships, as Brain+ aims to establish themselves as global market leaders by 2031, with revenue projections in several hundred millions of USD.